CJC-1295 (DAC) / Ipamorelin / GHRP-2 Blend
Three-way GH stack — one long-acting GHRH plus two ghrelin-receptor agonists.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About CJC-1295 (DAC) / Ipamorelin / GHRP-2 Blend
A 6mg vial containing 2mg each of CJC-1295 with DAC, Ipamorelin, and GHRP-2. The GHRH-plus-secretagogue logic is sound and well established: CJC-1295 raises baseline GHRH signalling while a ghrelin-receptor agonist amplifies the pulse, and each acts on a different receptor. The part that deserves scrutiny is having two ghrelin-receptor agonists in one vial. Ipamorelin and GHRP-2 both act on GHS-R1a, so the second adds limited GH release beyond the first while contributing its own cortisol, prolactin, and appetite effects — GHRP-2 raises food intake measurably in humans, which Ipamorelin largely does not. The half-lives also do not match: CJC-1295 with DAC persists for roughly 6–8 days, while both secretagogues clear within hours, so a schedule that suits one component cannot suit all three. No study has examined this specific three-way combination.
Key Benefits
- Combines two distinct receptor mechanisms for larger GH release
- Long-acting GHRH component sustains baseline signalling
- Single vial rather than three separate reconstitutions
Set a goal (top of the page) to see how CJC-1295 (DAC) / Ipamorelin / GHRP-2 Blend scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Increased appetite, driven mainly by the GHRP-2 component
- Water retention
- Transient cortisol and prolactin elevation
- Tingling or numbness in hands
- Flushing
- Combined effects of three peptides at a fixed ratio you cannot adjust
Legal & Regulatory Status
Research use only; not FDA-approved. Individual components have human data but no study exists on this three-way combination. All three components are WADA-prohibited.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- CJC-1295 dose-ranging trial in healthy adults (PMID 16352683)
- Pralmorelin (GHRP-2) drug profile (PMID 15230633)
- Phase 2 trial: ipamorelin for postoperative ileus (PMID 25331030)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.